These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer. NoeDominguez-Romero A; Zamora-Alvarado R; Servín-Blanco R; Pérez-Hernández EG; Castrillon-Rivera LE; Munguia ME; Acero G; Govezensky T; Gevorkian G; Manoutcharian K Hum Vaccin Immunother; 2014; 10(11):3201-13. PubMed ID: 25483665 [TBL] [Abstract][Full Text] [Related]
4. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles. Kang CY; Luo L; Wainberg MA; Li Y Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338 [TBL] [Abstract][Full Text] [Related]
5. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies. Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034 [TBL] [Abstract][Full Text] [Related]
6. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein. Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203 [TBL] [Abstract][Full Text] [Related]
7. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma. Gómez CE; Abaitua F; Rodríguez D; Esteban M Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077 [TBL] [Abstract][Full Text] [Related]
8. Antigenicity and predefined specificities of the multi-epitope vaccine in candidate consisting of neutralizing epitope and mutated epitopes suggested a new way against HIV-1 mutation. Tian H; Xiao Y; Qin L; Chen YH Immunobiology; 2001 Dec; 204(4):434-41. PubMed ID: 11776398 [TBL] [Abstract][Full Text] [Related]
9. Different immune response of mice immunized with conjugates containing multiple copies of either consensus or mixotope versions of the V3 loop peptide from human immunodeficiency virus type 1. Cruz LJ; Iglesias E; Aguilar JC; Cabrales A; Reyes O; Andreu D Bioconjug Chem; 2004; 15(5):1110-7. PubMed ID: 15366967 [TBL] [Abstract][Full Text] [Related]
10. A universal T cell epitope-containing peptide from hepatitis B surface antigen can enhance antibody specific for HIV gp120. Greenstein JL; Schad VC; Goodwin WH; Brauer AB; Bollinger BK; Chin RD; Kuo MC J Immunol; 1992 Jun; 148(12):3970-7. PubMed ID: 1376346 [TBL] [Abstract][Full Text] [Related]
11. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations. Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081 [TBL] [Abstract][Full Text] [Related]
12. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1. Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988 [TBL] [Abstract][Full Text] [Related]
14. A combinatorial peptide library around variation of the human immunodeficiency virus (HIV-1) V3 domain leads to distinct T helper cell responses. Estaquier J; Boutillon C; Georges B; Ameisen JC; Tartar A; Auriault C J Pept Sci; 1996; 2(3):165-75. PubMed ID: 9231325 [TBL] [Abstract][Full Text] [Related]
15. Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope. Zolla-Pazner S; Cohen SS; Krachmarov C; Wang S; Pinter A; Lu S Virology; 2008 Mar; 372(2):233-46. PubMed ID: 18061228 [TBL] [Abstract][Full Text] [Related]
16. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies. Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663 [TBL] [Abstract][Full Text] [Related]
17. Importance of conformation on the neutralizing antibody response to HIV-1 gp120. Steimer KS; Haigwood NL Biotechnol Ther; 1991; 2(1-2):63-89. PubMed ID: 1726963 [TBL] [Abstract][Full Text] [Related]
18. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells. Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249 [TBL] [Abstract][Full Text] [Related]
19. Dual specificity of a monoclonal anti-idiotypic antibody for HIV-1 neutralizing monoclonals 110.3 and 110.4 as well as the V3 loop of gp120. Connelly RJ; Kahn M; Blake J; Haffar OK; Thomas EK Virology; 1994 Dec; 205(2):554-7. PubMed ID: 7526543 [TBL] [Abstract][Full Text] [Related]
20. Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice. Shinoda K; Xin KQ; Jounai N; Kojima Y; Tamura Y; Okada E; Kawamoto S; Okuda K; Klinman D; Okuda K Vaccine; 2004 Sep; 22(27-28):3676-90. PubMed ID: 15315847 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]